Gilead Sciences (NASDAQ:GILD) EVP Norbert W. Bischofberger unloaded 90,000 shares of the stock in a transaction dated Wednesday, May 14th. The shares were sold at an average price of $80.65, for a total value of $7,258,500.00. Following the completion of the transaction, the executive vice president now directly owns 119,302 shares of the company’s stock, valued at approximately $9,621,706. Gilead Sciences, Inc. (NASDAQ:GILD) shares advanced 0.87% in last trading session and ended the day on $80.80. GILD Gross Margin is 77.80% and its return on assets is 19.10%. Gilead Sciences, Inc. (NASDAQ:GILD) quarterly performance is -0.50%.
On May 14, Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) announced that clinical data on Iclusig® (ponatinib) and AP26113, its investigational oral inhibitor of anaplastic lymphoma kinase (ALK), will be presented at the Annual Meeting of the American Society of Clinical Oncology being held in Chicago, May 30 to June 3, 2014. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) shares moved down -2.15% in last trading session and was closed at $6.36, while trading in range of $96.27 – $6.4. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) year to date (YTD) performance is -6.74%.
On May 14, 2014, MannKind Corporation (NASDAQ:MNKD) In the U.S. alone, roughly 1 of 12 people are managing diabetes. China has approximately 100 million diabetic patients as of 2012 statistics. Total global insulin sales have grown an average of $4 billion a year between 2011 and 2012 ($16.8B in 2011 and $20.8B in 2012). However, in 2013, sharp price increases sent the total market up to $35 billion. By 2018, total insulin sales are expected to increase 66% to reach more than $58 billion due to continued increase in price and patients. MannKind Corporation (NASDAQ:MNKD) ended the last trading day at $7.02. Company weekly volatility is calculated as 4.96% and price to cash ratio as 38.26. MannKind Corporation (NASDAQ:MNKD) showed a positive weekly performance of 12.86%.
Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN)sees cash, cash equivalents balance sufficient to fund company into 1H16. The company said, “We continue to enroll patients in each of our three clinical trials as expected, and as planned for. By the end of 2014, we expect to achieve key milestones in each trial. In Q4 we expect to have data from our Phase I trial of Supinoxin in cancer patients with solid tumors. We are also scheduled to complete enrollment of patients in our Phase Ib clinical trial of RX-3117 by the end of 2014. During Q4 of this year, we anticipate completing the safety portion of our Phase II trial for metastatic renal cell carcinoma.” Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) weekly performance is 23.42%. On last trading day company shares ended up $0.975. Analysts mean target price for the company is $2.83. Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) distance from 50-day simple moving average (SMA50) is -10.35%.